Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Nov;44(11):1859-1869.
doi: 10.1007/s00134-018-5378-3. Epub 2018 Oct 5.

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Affiliations
Randomized Controlled Trial

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Pratik Sinha et al. Intensive Care Med. 2018 Nov.

Abstract

Purpose: Using latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.

Methods: LCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.

Results: The two-class LCA model best fit the population. Forty percent of the patients were classified as the "hyper-inflammatory" subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.

Conclusions: LCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.

Keywords: ARDS; Latent class analysis; Statins; Subphenotypes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Standardized values for continuous class-predicting variables. The variables are sorted from left to right in descending order for the difference in values between the hyper-inflammatory and hypo-inflammatory subphenotype. Standardized values were calculated by assigning the mean of the variables as 0 and standard deviation as 1. BMI = body mass index; SBP = systolic blood pressure; ICAM-1 = intercellular adhesion molecule-1; IL-6 = Interleukin 6; IL-8 = Interleukin 8; Mean Air Press = mean airway pressure; PAI-1 = plasminogen activator inhibitor-1; PEEP = positive end-expiratory pressure; Plat Press = plateau pressure; sTNFr1 = tumor necrosis factor receptor-1; VE = minute ventilation; VT = tidal volume; WBC= white blood cell count.
Fig. 2
Fig. 2
Kaplan-Meier survival curves to 60 days for patients in the SAILS trial; the population was stratified by ARDS subphenotype and treatment (rosuvastatin vs placebo). Comparison of curves using Cox Proportional Hazards modeling; p = 0.45 subphenotype 1 (hypo-inflammatory), p = 0.331 subphenotype 2 (hyper-inflammatory).

References

    1. Frank AJ, Thompson BT, (2010) Pharmacological treatments for acute respiratory distress syndrome. Curr Opin Crit Care 16: 62–68 - PubMed
    1. Bosma KJ, Taneja R, Lewis JF, (2010) Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs 70: 1255–1282 - PMC - PubMed
    1. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG, (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288: L1026–1032 - PubMed
    1. Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S, Flanders SA, (2012) Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 125: 1111–1123 - PubMed
    1. Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF, (2009) Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179: 1107–1114 - PMC - PubMed

Publication types

MeSH terms

Substances